Complejo Hospitalario de Toledo -ko ikertzaileekin lankidetzan egindako argitalpenak (81)

2024

  1. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723

  2. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM

    Journal of Allergy and Clinical Immunology: In Practice

  3. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 7, pp. 1921-1937

2023

  1. Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547

  2. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  3. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1347-1359

  4. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality

    The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919

  5. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

    Cancers, Vol. 14, Núm. 10

  3. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

    Blood, Vol. 139, Núm. 4, pp. 572-583

  4. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  5. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2039-2051

  6. Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features

    Clinical and Translational Allergy, Vol. 12, Núm. 3

  7. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  8. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

2021

  1. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144

  2. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086

  3. Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis

    American Journal of Human Genetics, Vol. 108, Núm. 2, pp. 284-294

  4. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders

    Annals of Allergy, Asthma and Immunology, Vol. 127, Núm. 4, pp. 427-434